Amoy Diagnostics Co

Amoy Diagnostics Co Interest Coverage

The Interest Coverage Ratio of Amoy Diagnostics Co (300685.SZ) as of Oct 28, 2026 is 10.78. In the previous year, Interest Coverage Ratio was 12.44 — a change of -13.32% (lower).

Interest Coverage

10.78

YoY

-13.32%

Last updated:

Interest Coverage Ratio of Amoy Diagnostics Co is 2024 10.78 . Interest Coverage Ratio of Amoy Diagnostics Co was 2023 12.44 . It decreases by -13.32% lower compared to the previous year.

The Amoy Diagnostics Co Interest Coverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Interest Coverage
Date
Interest Coverage
Jan 1, 2017
46.24 CNY
Jan 1, 2018
13.08 CNY
Jan 1, 2019
17.28 CNY
Jan 1, 2020
30.17 CNY
Jan 1, 2021
159.32 CNY
Jan 1, 2022
9.89 CNY
Jan 1, 2023
12.44 CNY
Jan 1, 2024
10.78 CNY
The Amoy Diagnostics Co Interest Coverage history
YEARInterest CoverageYoY
10.78-13.32%
12.44+25.73%
9.89-93.79%
159.32+428.06%
30.17+74.58%
17.28+32.08%
13.08-71.70%
46.24+212.00%
14.82+114.91%
6.90—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Amoy Diagnostics Co Stock analysis

What does Amoy Diagnostics Co do? Amoy Diagnostics Co., Ltd. generates revenue through the sale of tumor precision molecular diagnostic products, including ADx-ARMS, Super-ARMS, NGS, and FISH testing reagents. These reagents are used for detecting non-small cell lung cancer, colorectal cancer, thyroid cancer, and melanoma in tumor tissue specimens and liquid biopsies. The company also offers data software for gene sequencing data analysis and provides testing services via its medical testing institutions for lung cancer, colorectal cancer, and breast cancer. Revenue streams include reagent sales, software licensing, and diagnostic testing services. The primary customers are medical institutions and healthcare providers requiring tumor molecular diagnostics. The ADx-ARMS product line targets tumor tissue specimen detection, while Super-ARMS serves liquid biopsy applications. NGS and FISH products support comprehensive tumor genetic analysis. Testing services focus on lung, colorectal, and breast cancer diagnostics, catering to hospitals and clinics specializing in oncology. The company’s offerings align with the demand for precise cancer diagnosis and treatment planning. Amoy Diagnostics’ revenue model combines product sales with service-based offerings. Reagent products like ADx-ARMS and Super-ARMS are sold to medical facilities for routine tumor testing. Data software for gene sequencing analysis is licensed to research institutions and hospitals. Testing services through its medical testing institutions provide direct diagnostic solutions for specific cancers, enhancing customer retention through integrated service packages. Amoy Diagnostics Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Amoy Diagnostics Co stock

Interest Coverage Ratio of Amoy Diagnostics Co is 10.78 in 2024.

Interest Coverage Ratio of Amoy Diagnostics Co changed from 12.44 to 10.78, representing a -13.32% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Interest Coverage Ratio Amoy Diagnostics Co since 2006 – with annual values, charts, and detailed analysis.

The Interest Coverage ratio measures a company's ability to pay interest on its debt. Higher ratios indicate greater financial strength and lower default risk.

Interest Coverage = EBIT / Interest Expense

A 'good' varies by industry and company stage. On Eulerpool, you can compare Interest Coverage Ratio's Amoy Diagnostics Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Amoy Diagnostics Co

All Key Metrics — Amoy Diagnostics Co